Evidence map›Paper›PMID 34594878›Full record

ArticleChina CDC weekly2021

Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease - Hebei Province, China, September-December, 2019.

Yan Li, Ying Ma, Zhijie An, Chenyan Yue, Yamin Wang, Liye Wang, Yunqiu Liu, Xiaodong Yuan, Shuping Zhang, Qiang Ye and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yan LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Ying MaKailuan General Hospital, Tangshan, Hebei, China.
Zhijie AnNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Chenyan YueNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Yamin WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Liye WangKailuan General Hospital, Tangshan, Hebei, China.
Yunqiu LiuKailuan General Hospital, Tangshan, Hebei, China.
Xiaodong YuanKailuan General Hospital, Tangshan, Hebei, China.
Shuping ZhangKailuan General Hospital, Tangshan, Hebei, China.
Qiang YeNational Institute for Food and Drug Control, Beijing, China.
Hong LiNational Institute for Food and Drug Control, Beijing, China.
Keli LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Huaqing WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Chinese Center For Disease Control and Prevention · CNKailuan General Hospital · CNNational Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WHAT IS ALREADY KNOWN ON THIS TOPIC?: The global burden of chronic obstructive pulmonary disease (COPD) is serious. Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for COPD patients to decrease AECOPD due to pneumococcus, but evidence on the immunogenicity of PPSV23 in COPD patients is limited. WHAT IS ADDED BY THIS REPORT?: This study showed good immunogenicity of one dose of PPSV23 in COPD patients. Antibody levels against all 23 vaccine serotypes were assessed before and four weeks after vaccination of COPD patients with one dose of PPSV23. The percent of COPD patients who had two-fold increases in pneumococcal antibody levels following vaccination ranged from 65.2% (serotype 3) to 94.4% (serotype 2). There were statistically significant differences in immunogenicity by serotype. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: This study supports current recommendations for PPSV23 vaccination of COPD patients in China to provide protection from pneumococcal diseases.

Identifiers

PMID34594878
PMCPMC8393071
OpenAlexW3156075236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.